ストックスクリーナーアプリを入手
1.16
0.87%
0.01
アフターアワーズ：
1.14
-0.02
-1.72%
前日終値:
$1.15
開ける：
$1.18
24時間の取引高:
342.26K
Relative Volume:
0.11
時価総額：
$5.00M
収益：
-
当期純損益:
$-16.08M
株価収益率:
-0.0337
EPS:
-34.43
ネットキャッシュフロー:
$-11.54M
1週間 パフォーマンス:
+1.75%
1か月 パフォーマンス:
+63.38%
6か月 パフォーマンス:
-34.83%
1年 パフォーマンス:
-88.19%
1日の値動き範囲:
$1.13
$1.21
1週間の範囲:
$1.11
$1.34
52週間の値動き範囲:
$0.5933
$12.00
Bio Path Holdings Inc Stock (BPTH) Company Profile
名前
Bio Path Holdings Inc
セクター
電話
(832) 742-1357
住所
4710 BELLAIRE BOULEVARD, BELLAIRE, TX
BPTH を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BPTH
Bio Path Holdings Inc
|
1.16 | 5.00M | 0 | -16.08M | -11.54M | -34.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.11 | 104.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.15 | 78.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
621.29 | 37.15B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.28 | 30.22B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.79 | 27.76B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bio Path Holdings Inc Stock (BPTH) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-03-11 | 開始されました | ROTH Capital | Buy |
| 2017-11-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-08-10 | 繰り返されました | Maxim Group | Buy |
| 2016-04-18 | 開始されました | Rodman & Renshaw | Buy |
| 2014-06-02 | 再開されました | Maxim Group | Buy |
| 2014-05-09 | 開始されました | Maxim Group | Buy |
すべてを表示
Bio Path Holdings Inc (BPTH) 最新ニュース
Bio-Path (NASDAQ:BPTH) Earns Sell Rating from Analysts at StockNews.com - Defense World
Is This Penny Stock a Buy After a 180% Rally? - MSN
Is This Penny Stock A Buy After A 180% Rally? - Barchart
Bio-Path Holdings Advances Clinical Trials and Secures $4 Million in Funding - Citybuzz
Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com - Defense World
Studies of Bio-path’s BP-1001-A show potential in obesity, diabetes - BioWorld Online
Bio-Path Rockets To 4-Month High As Obesity Drug Shows Promise For Diabetes: Retail In Celebration Mode - Asianet Newsable
Bio-Path Holdings (BPTH) Surges Over 406% Following Positive Pre - GuruFocus.com
Bio-Path Holdings: Promising Preclinical Results for BP1001-A - TipRanks
MRVI Stock Drops 5% Amidst Biotech Sector Decline - GuruFocus.com
Nasdaq Jumps 100 Points, US Initial Jobless Claims Decline - Benzinga
Bio-Path More Than Doubles on Preclinical Results of BP1001-A for Obesity - MarketWatch
Industry Leader Climet Partners with Phizzle; One of the First Joint TCO/ROI Value Proposition in Pharma Manufacturing - Newsfile
Bio-Path Holdings Shares Were On The Rise: What's Going On? - Benzinga
Gold Falls Sharply, Lamb Weston Shares Plunge - Benzinga
Innovative therapies and military tech drive early trading gains - RagingBull
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Artificial Intelligence (AI) News Live Feed - StockTitan
Wall Street-Heavily Traded - WDRB
Bio-Path (BPTH) Stock Rides High On Promising Trial Results - Stocks Telegraph
Clinical Trials News Live Feed - StockTitan
Bio-Path reports potential obesity treatment success - Investing.com
Bio-Path's Breakthrough Drug Shows Promise in Diabetes Treatment, Phase 1 Trial Set for 2025 - StockTitan
Bio-Path (NASDAQ:BPTH) Now Covered by StockNews.com - Defense World
VueReal Showcases Industry-First MicroLED Design Reference Kits at CES 2025, Driving Global Innovation Across Key Industries - Newsfile
Bio-Path Holdings Faces Nasdaq Compliance and Strategic Changes - MSN
Bullfrog AI CFO Passes Away - Defense World
Rafael Holdings Reports First Quarter Fiscal 2025 Financial ResultsNEWARK, NJ – December 11, 2024 – Rafael Holdings, Inc. (NYSE: RFL) released its financial results for the first quarter of fiscal year 2025, ended October 31, 2024. The company announ - Defense World
Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients - Defense World
Bio-Path Holdings faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Bio-Path Holdings faces Nasdaq delisting over share price - Investing.com
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 24 - The Kingston Whig-Standard
Bio-Path Holdings Shifts Focus to Metabolic Program - TipRanks
CNB Financial Services, Inc. goes ex dividend tomorrow - MSN
VueReal Highlights Revolutionary MicroLED Solutions at CES 2025 - Newsfile
Bio-Path refocuses on diabetes drug amid trial challenges By Investing.com - Investing.com South Africa
Stonegate Capital Partners Updates Coverage on Aemetis, Inc. (AMTX) Q3 2024 - Newsfile
Bio-Path refocuses on diabetes drug amid trial challenges - Investing.com India
Tecnoglass Sets Record Date for Previously-Announced 36% Increase to Fourth Quarter 2024 Dividend - The Manila Times
Bio-Path Pivots to Diabetes Drug Development, Unveils Strategic Shift in Clinical Pipeline - StockTitan
BPTH stock touches 52-week low at $0.6 amid sharp annual decline - Investing.com Canada
Full Stock Market News from 2024-12-06 - StockTitan
Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH) - Defense World
Bio-Path Holdings Expands DNAbilize® Technology Applications - MSN
Bio-Path (BPTH) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - MSN
Bio-Path Holdings Inc (BPTH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial ... By GuruFocus - Investing.com Canada
Meridianbet (GMGI) and Crvena Zvezda Seal Euroleague's First Logo Integration Deal - Newsfile
Bio-Path Holdings Inc (BPTH) Q3 2024 Earnings Call Highlights: S - GuruFocus.com
Bio-Path Holdings Inc (BPTH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
Bio Path Holdings Inc (BPTH) 財務データ
収益
当期純利益
現金流量
EPS
0.60%
2.24%
大文字化:
|
ボリューム (24 時間):